{"id":50896,"date":"2022-11-15T19:02:11","date_gmt":"2022-11-15T18:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/"},"modified":"2022-11-15T19:02:11","modified_gmt":"2022-11-15T18:02:11","slug":"solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/","title":{"rendered":"Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nSolaris and Wildtype signed an agreement to collaboratively develop a new generation of bioreactors to foster large-scale production of cultivated seafood.\n<\/li>\n<li>\nBioreactors are one of the most important pieces of equipment in the productive infrastructure of cell-cultured food proteins and new cultivated food technologies.\n<\/li>\n<\/ul>\n<p>PORTO MANTOVANO, Italy&#8211;(BUSINESS WIRE)&#8211;Donaldson brand Solaris Biotech, a leading innovator and manufacturer of bioreactors, fermenters and tangential flow filtration systems has entered an agreement with Wildtype, a San Francisco-based company focused on creating cultivated seafood. The two companies will engage in a collaborative development program to design a next generation family of bioreactor systems to help meet the growing demand for seafood.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221115006265\/en\/1638380\/5\/Solaris_industrial_scale_bioreactor_systems.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221115006265\/en\/1638380\/21\/Solaris_industrial_scale_bioreactor_systems.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20221115006265\/en\/1638379\/5\/solaris-biotech-brand-logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221115006265\/en\/1638379\/21\/solaris-biotech-brand-logo.jpg\"><\/a><\/p>\n<p>\nFood is fundamental to our existence, and food demand is increasing with rising income levels and a multiplying global population. Alternative proteins are experiencing rapid growth as a result of these trends, and cell cultivated proteins are at the forefront of these innovations. \u201cSolaris, with our specialized bioprocessing equipment, is uniquely positioned to play a significant role in the advancement of new cultured food technologies,\u201d said Matteo Brognoli, Managing Director of Solaris. \u201cAlternative proteins have become the fastest growing segment for bioreactor systems and we are proud that our cultivators are the enabling technology for this leap in the food industry.\u201d\n<\/p>\n<p>\n\u201cWildtype is on a mission to produce the cleanest, most delicious seafood on the planet,\u201d said Justin Kolbeck, Wildtype CEO. \u201cAnnual global seafood consumption is expected to increase an additional 23 million tons by 2030 and one of the most important pieces in the productive infrastructure are the cultivators used to grow cells. With Solaris\u2019 technologically advanced solutions we have found the right partner to help us scale and make our products more affordable and accessible.\u201d\n<\/p>\n<p>\n<b>About Solaris<\/b>\n<\/p>\n<p>\nSolaris, a Donaldson brand, is a leading innovator and manufacturer of fermenters, bioreactors, tangential flow (TFF) and depth (FFF) filtration systems used for a variety of applications in the pharmaceutical, biopharmaceutical and food industries. Its product and development teams create solutions at all scales, from benchtop R&amp;D systems to complete engineered solutions tailored to individual customer needs. Since November 2021, Solaris has been a part of Donaldson Company (NYSE: DCI) and its expansion into life sciences. Discover the full scope of Solaris products and capabilities at solarisbiotech.com.\n<\/p>\n<p>\n<b>About Wildtype<\/b>\n<\/p>\n<p>\nWildtype is on a mission to create the cleanest, most sustainable seafood on the planet, starting with sushi-grade salmon. The company is pioneering cellular agriculture to protect wild species and our oceans, and to reverse trends of global food insecurity. Wildtype will provide consumers with a new option for real seafood that provides the same nutritional benefits as the most pristine wild-caught fish, without common contaminants such as mercury, microplastics, antibiotics or pesticides.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nPrimary contact:<br \/>\n<br \/>Becky Cahn (+1 952.703.4590)<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o:&#67;&#111;&#x72;&#x70;or&#97;&#116;&#x65;&#x2e;Co&#109;&#x6d;&#x75;&#x6e;i&#99;&#97;&#x74;&#x69;&#x6f;n&#115;&#64;&#x44;&#x6f;&#x6e;a&#108;&#100;&#x73;&#x6f;&#x6e;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x43;&#111;r&#x70;&#111;&#114;&#x61;&#x74;&#101;&#46;&#x43;&#111;m&#x6d;&#x75;&#110;i&#x63;&#97;t&#x69;&#x6f;&#110;s&#x40;&#68;o&#x6e;&#x61;&#108;d&#x73;&#111;n&#x2e;&#x63;&#111;&#x6d;<\/a>\n<\/p>\n<p>\nSecondary contact (Italian inquiries):<br \/>\n<br \/>Raffaello Porro (+393351015456)<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;:&#x52;&#x61;f&#102;&#x61;e&#108;&#x6c;o&#46;&#x70;o&#114;&#x72;o&#64;&#x73;&#x74;&#117;&#x64;&#x69;&#111;&#x72;&#x70;r&#x2e;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x52;&#x61;&#102;&#102;ae&#x6c;&#x6c;&#x6f;&#46;po&#x72;&#x72;&#x6f;&#64;&#115;t&#x75;&#x64;&#x69;&#111;&#114;p&#x72;&#x2e;&#x63;&#111;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Solaris and Wildtype signed an agreement to collaboratively develop a new generation of bioreactors to foster large-scale production of cultivated seafood. Bioreactors are one of the most important pieces of equipment in the productive infrastructure of cell-cultured food proteins and new cultivated food technologies. PORTO MANTOVANO, Italy&#8211;(BUSINESS WIRE)&#8211;Donaldson brand Solaris Biotech, a leading innovator and &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50896","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Solaris and Wildtype signed an agreement to collaboratively develop a new generation of bioreactors to foster large-scale production of cultivated seafood. Bioreactors are one of the most important pieces of equipment in the productive infrastructure of cell-cultured food proteins and new cultivated food technologies. PORTO MANTOVANO, Italy&#8211;(BUSINESS WIRE)&#8211;Donaldson brand Solaris Biotech, a leading innovator and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-15T18:02:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221115006265\/en\/1638380\/21\/Solaris_industrial_scale_bioreactor_systems.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production\",\"datePublished\":\"2022-11-15T18:02:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/\"},\"wordCount\":481,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221115006265\\\/en\\\/1638380\\\/21\\\/Solaris_industrial_scale_bioreactor_systems.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/\",\"name\":\"Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221115006265\\\/en\\\/1638380\\\/21\\\/Solaris_industrial_scale_bioreactor_systems.jpg\",\"datePublished\":\"2022-11-15T18:02:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221115006265\\\/en\\\/1638380\\\/21\\\/Solaris_industrial_scale_bioreactor_systems.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221115006265\\\/en\\\/1638380\\\/21\\\/Solaris_industrial_scale_bioreactor_systems.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/","og_locale":"en_US","og_type":"article","og_title":"Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production - Pharma Trend","og_description":"Solaris and Wildtype signed an agreement to collaboratively develop a new generation of bioreactors to foster large-scale production of cultivated seafood. Bioreactors are one of the most important pieces of equipment in the productive infrastructure of cell-cultured food proteins and new cultivated food technologies. PORTO MANTOVANO, Italy&#8211;(BUSINESS WIRE)&#8211;Donaldson brand Solaris Biotech, a leading innovator and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-15T18:02:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221115006265\/en\/1638380\/21\/Solaris_industrial_scale_bioreactor_systems.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production","datePublished":"2022-11-15T18:02:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/"},"wordCount":481,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221115006265\/en\/1638380\/21\/Solaris_industrial_scale_bioreactor_systems.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/","url":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/","name":"Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221115006265\/en\/1638380\/21\/Solaris_industrial_scale_bioreactor_systems.jpg","datePublished":"2022-11-15T18:02:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221115006265\/en\/1638380\/21\/Solaris_industrial_scale_bioreactor_systems.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221115006265\/en\/1638380\/21\/Solaris_industrial_scale_bioreactor_systems.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/solaris-biotech-and-wildtype-announce-agreement-for-large-scale-bioreactors-for-cultivated-seafood-production\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Solaris Biotech and Wildtype Announce Agreement for Large-scale Bioreactors for Cultivated Seafood Production"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50896"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50896\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}